Ticker LaunchReverse merger · Completed · HURA
TuHURA Biosciences, Inc.
Reverse merger with Kintara Therapeutics, Inc. (KTRA)
TuHURA Biosciences, Inc. merged into Kintara Therapeutics, Inc. (KTRA), a Nasdaq-listed clinical-stage cancer drug developer, in a reverse merger that takes the private company public. The deal was announced on Apr 3, 2024 and closed on Oct 18, 2024. The combined company trades as TuHURA Biosciences, Inc. (HURA) on Nasdaq.
TuHURA Biosciences is a Phase 3 registration-stage immuno-oncology company developing technologies to overcome resistance to cancer immunotherapy, led by IFx-2.0, a personalized cancer vaccine for first-line Merkel cell carcinoma used with Keytruda.
- Status
- Completed
- Private company
- TuHURA Biosciences, Inc.
- Public company
- Kintara Therapeutics, Inc. (KTRA)
- Public company business before
- Nasdaq-listed clinical-stage cancer drug developer
- Announced
- Apr 3, 2024
- Closed
- Oct 18, 2024
- Combined company
- TuHURA Biosciences, Inc. (HURA)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Ownership split between private and public holders
- Concurrent financing and investors
- Contingent value rights (CVR)
- Reverse stock split
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
Other completed reverse mergers
- Lomond Therapeutics, Inc.into Venetian-1 Acquisition Corp. · Nov 1, 2024
- NAYA Biosciences, Inc.into INVO Bioscience, Inc. · Oct 11, 2024
- Pharmagesic (Holdings) Inc. (Wex Pharmaceuticals)into Virios Therapeutics, Inc. · Oct 7, 2024
- OnKure, Inc.into Reneo Pharmaceuticals, Inc. · Oct 4, 2024
- Polomar Specialty Pharmacy, LLCinto Trustfeed Corp. · Sep 30, 2024
- Oruka Therapeutics, Inc.into ARCA biopharma, Inc. · Aug 29, 2024